CTOS 10th
Annual Meeting
November 11–13, 2004
Thursday 11 November 2004 |
|
| 11:00
am – 5:00 pm |
Registration
|
| 11:00am – 5:00 pm |
Poster
Set-Up |
| 1:00 pm – 1:15 pm |
|
| 1:15 pm –
5:00 pm |
Radiology Symposium |
|
|
| 5:00 pm – 6:00 pm |
Welcome
Reception |
| 6:00 pm – 9:00 pm |
SARC
Dinner |
| Friday 12 November 2004 |
|||
| 6:30 am – 5:00 pm |
Registration
|
||
| 7:00 am – 8:00 am |
Continental Breakfast
|
||
| 7:00 am – 8:00 am |
Poster Viewing |
||
| 7:00 am – 8:00 am |
Executive Committee
Meeting |
||
| 8:00 am – 9:15
am |
Special Topic:
Patient Selection and Treatment Options for Primary Sarcoma
and Metastases to Spine |
||
| 1 | (342)
IMAGE GUIDED INTENSITY MODULATED RADIOTHERAPY (IMRT) WITH
NONINVASIVE IMMOBILIZATION FOR THE HIGH DOSE TREATMENT OF
PRIMARY TUMORS OF THE SPINAL COLUMN |
||
| 9:15 am – 9:30 am |
Coffee Break
|
||
| 9:30 am – 10:30 am |
Surgery: Staging and
Prognostication |
||
| 1 | (252)
VALIDATION AND ADAPTATION OF A NOMOGRAM FOR PREDICTING SURVIVAL
OF EXTREMITY SOFT TISSUE SARCOMA USING A THREE GRADE SYSTEM |
||
| 2 | (296)
MULTICENTRIC EVALUATION OF THE FRENCH SURGICAL SYSTEM IN
SOFT TISSUE SARCOMA (STS) |
||
| 3 | (294)
DECISION MAKING IN ORTHOPAEDIC ONCOLOGY |
||
| 10:30 am – 12:00 pm |
Surgery: Local Control
and Outcomes |
||
| 1 | (317)
OUTCOME FOLLOWING PELVIC SARCOMA RESECTION RECONSTRUCTED
WITH SADDLE PROSTHESIS |
||
| 2 | (288)
ADDUCTOR COMPARTMENT SOFT TISSUE SARCOMAS- DOES METHOD OF
TREATMENT AFFECT OUTCOME? |
||
| 3 | (231)
ENDOPROSTHETIC VS. “CONDYLE-SPARING” INTERCALARY ALLOGRAFTS
FOR DISTAL FEMORAL OSTEOSARCOMA: A COMPARISON OF LONG-TERM
FOLLOW-UP |
||
| 4 | (311)
UNICOMPARTMENTAL OSTEOARTICULAR ALLOGRAFTS OF THE KNEE:
SURVIVAL ANALYSIS AND COMPLICATIONS |
||
| 5 | (332)
FUNCTIONAL AND ONCOLOGIC OUTCOME AFTER COMBINED ALLOGRAFT
AND TOTAL HIP ARTHROPLASTY RECONSTRUCTION OF LARGE BONY
PELVIC DEFECTS FOLLOWING TUMOUR RESECTION |
||
| 12:00 pm – 1:15 pm |
Lunch |
||
| 12:00 pm – 1:15 pm |
Board of Directors
Meeting |
||
| 1:15 pm – 3:00 pm |
Osteosarcoma and Related
Topics |
||
| 1 | (261)
POST CHEMOTHERAPY SERUM ALKALINE PHOSPHATASE IS AN INDICATOR
OF CHEMOTHERAPY RESPONSE AND SURVIVAL IN ADULTS TREATED
FOR LOCALISED OSTEOSARCOMA |
||
| 2 | (280)
PET IN OSTEOSARCOMA: THE CORRELATION BETWEEN PERCENT NECROSIS
AND RESPONSE AS SEEN BY PET |
||
| 3 | (345)
PREDICTING OUTCOME IN OSTEOSARCOMA USING A GENOME-WIDE APPROACH |
||
| 4 | (257)
TREATMENT OF RELAPSED OSTEOSARCOMA AFTER CONTEMPORARY THERAPY:
THE MEMORIAL SLOAN-KETTERING EXPERIENCE |
||
| 5 | (269)
PRIMARY SPINDLE CELL SARCOMA OF BONE – AN ASSESSMENT OF
OUTCOME |
||
| 3:00 pm – 3:45 pm |
Coffee Break & Poster Viewing | ||
| 3:45 pm – 5:00 pm |
Medical Oncology |
||
| 1 | (347)
ACQUIRED RESISTANCE TO IMATINIB IN PROGRESSIVE GASTROINTESTINAL
STROMAL TUMORS DUE TO MULTIPLE SYNCHRONOUS KINASE MUTATIONS
IN DIFFERENT EXONS OF KIT |
||
| 2 | (290)
EARLY AND LATE RESISTANCE TO IMATINIB (IM) IN ADVANCED GASTRO-INTESTINAL
STOMAL TUMORS (GIST) ARE PREDICTED BY DIFFERENT PROGNOSTIC
FACTORS: AN ANALYSIS OF THE EORTC-ISG-AGITG RANDOMIZED TRIAL |
||
| 3 | (263)
A COMPARISON OF PATTERNS OF TUMOR RESPONSE TO MOLECULAR-TARGETED
THERAPY IN GIST AND CHORDOMA |
||
| 4 | (227)
DISEASE PROGRESSION IN PATIENTS WITH METASTATIC GASTROINTESTINAL
STROMAL TUMOR (GIST) RECEIVING GLEEVEC (IMATINIB): THE EFFECT
OF DRUG DOSAGE |
||
| 5 | (250)
DOPAMINE MAY DECREASE NEPHROTOXICITY IN PATIENTS RECEIVING
HIGH-DOSE IFOSFAMIDE |
||
| 5:00 pm – 5:30 pm |
Advocacy
Groups |
||
| 1 | Sarcoma Foundation of America , Jody Cummings | ||
| 2 | Sarcoma Alliance , David Murphy | ||
| 3 | Liferaft Group , Norman Scherzer | ||
| 5:30 pm – 6:00 pm |
Members
Business Meeting |
||
| 7:00 pm – 8:00 pm |
Reception |
||
| 8:00 pm – 11:00 pm |
Dinner |
||
Saturday 13 November 2004 |
||
| 6:30 am – 5:00 pm |
Registration
|
|
| 7:00 am – 8:00 am |
Continental Breakfast
|
|
| 7:00 am – 8:00 am |
Poster Viewing
|
|
| 8:00 am – 9:00 am |
Pathology
|
|
| 1 | (344)
AMPLIFICATION AND OVEREXPRESSION OF COPS3 IN OSTEOSARCOMA:
RELATIONSHIP TO P53 MUTATION AND PATIENT OUTCOME |
|
| 2 | (259)
CD56 EXPRESSION IN BONE AND OSTEOBLASTIC NEOPLASIA: A NOVEL
OSTEOBLAST MARKER YOUNG INVESTIGATOR AWARD WINNER |
|
| 3 | (277)
E2F3 OVEREXPRESSION IN SOFT TISSUE SARCOMA DEVELOPMENT |
|
| 4 | (329)
P450 3A AS A MEDIATOR OF CHEMOTHERAPY RESISTANCE IN PATIENTS
WITH SOFT TISSUE SARCOMAS. |
|
| 9:00 am – 10:00
am |
Radiation Oncology
|
|
| 1 | (286)
FIVE YEAR RESULTS OF A RANDOMIZED PHASE III TRIAL OF PRE-OPERATIVE
VS POST-OPERATIVE RADIOTHERAPY IN EXTREMITY SOFT TISSUE
SARCOMA |
|
| 2 | (234)
MORTALITY AFTER APPARENT CURE OF SOFT TISSUE SARCOMA USING
COMBINED MODALITY THERAPY |
|
| 3 | (308)
INTENSITY MODULATED RADIATION THERAPY (IMRT) FOR PRIMARY
SOFT TISSUE SARCOMA OF THE EXTREMITY: PRELIMINARY RESULTS |
|
| 4 | (327)
POST-IRRADIATION RECOVERY OF GROWTH PLATE FUNCTION IS DRIVEN
BY EXPANSIONS OF REGENERATIVE CLONES |
|
| 10:00am – 10:15
am |
Coffee Break and Poster
Viewing |
|
| 10:15 am – 11:15
am |
Nina Axelrad Lecture:
Cytogenetic
Insights in Mesenchymal Tumors |
|
| 11:15 am –
12:45 pm |
Biology
Part I: Basic Science Models and Molecular Profiles
|
|
| 1 | (281)
HIGH EXPRESSION OF EZRIN, A DETERMINANT OF METASTATIC BEHAVIOR,
IN EWING'S SARCOMA (ES) |
|
| 2 | (339)
CONDITIONAL KNOCKOUT OF P53 IN MESENCHYMAL CELLS OF MICE
RESULTS IN OSTEOSARCOMAS |
|
| 3 | (351)
TRANSFORMATION OF MESENCHYMAL STEM CELLS BY THE RETROVIRUS-MEDIATED
GENE TRANSFER |
|
| 4 | (242)
MOLECULAR PROFILING OF GIANT CELL TUMOURS |
|
| 5 | (313)
MOLECULAR ANALYSIS OF SPORADIC AND NEUROFIBROMATOSIS TYPE
1 (NF1)-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS |
|
| 6 | (271)
GENE EXPRESSION PROFILES RELATE TO GENE FUSION TYPE AND
METASTASIS IN SYNOVIAL SARCOMA |
|
| 12:45 pm – 1:45
pm |
Lunch |
|
| 1:45 pm – 2:45 pm |
Biology Part II: Translation:
Bench to Clinic |
|
| 1 | (256)
17-AAG INHIBITS SYNOVIAL SARCOMA CELL GROWTH IN VITRO |
|
| 2 | (350)
FIBROBLAST GROWTH FACTOR SIGNALS AS POTENTIAL MOLECULAR
TARGETS IN SYNOVIAL SARCOMA YOUNG INVESTIGATOR AWARD WINNER |
|
| 3 | (338)
HEDGEHOG SIGNALING REGULATES PROLIFERATION IN CHONDROSARCOMA:
IMPLICATIONS FOR NOVEL THERAPY |
|
| 2:45 pm – 3:00 pm |
Coffee Break and
Poster Viewing |
|
| 3:00 pm – 3:30 pm |
Special Topic: Molecular
Analysis of Sarcomas |
|
| 3:30 pm – 3:45 pm |
1.
Sarcomas with Aberrant Transcription Factors-Biology and
Expression Profiling |
|
| 3:45 pm –
4:00 pm |
2. Extraskeletal
Myxoid Chondrosarcoma: Two Views of the Same Tumor
|
|
| (302)
CASE REPORT: EXTRASKELETAL MYXOID CHONDROSARCOMA (EMC) |
||
| 4:00 pm – 4:30 pm |
3.
Extraskeletal myxoid chondrosarcoma: two views of the same
tumor |
|
| 4:30 pm – 5:00 pm |
4.
Molecular cytogenetics of osteosarcoma |
|
| 5:15 pm – 5:45 pm |
Collaborative Studies
Discussion |
|
| 5:45 pm – 6:00 pmSalon de Saisons |
Closing Remarks
|
|